If you were injured after taking compounded semaglutide — from a compounding pharmacy, telehealth weight-loss platform, or med-spa — your situation is fundamentally different from cases involving brand-name Ozempic, Wegovy, or Mounjaro. Our firm is not currently accepting compounded GLP-1 injury cases. This page tells you why, and tells you what your realistic options are.
What is “compounded” semaglutide?
A compounding pharmacy is a state-licensed pharmacy that prepares custom medications for individual patients. Under federal law (21 U.S.C. §§ 503A and 503B), compounding pharmacies are permitted to compound a copy of an FDA-approved drug while that drug is on the FDA shortage list. They are not permitted to do so otherwise.
- FDA placed semaglutide on the drug shortage list in 2022.
- Compounding pharmacies, telehealth platforms, and wellness clinics produced large volumes of compounded semaglutide and tirzepatide during the shortage.
- FDA removed semaglutide from the shortage list in early 2025; tirzepatide had been removed previously.
- After removal, compounders were required to wind down compounded production; FDA enforcement is ongoing and litigation between compounders and FDA is active.
Why is there no MDL for compounding-pharmacy cases?
Federal multidistrict litigation works best when many plaintiffs share a common defendant and a common product. Brand-name GLP-1 cases share two well-funded defendants — Novo Nordisk and Eli Lilly — and FDA-approved products with traceable batches and standardized labeling. Compounded products are different in four important ways:
- Compounded products are made in many different facilities, with many different formulations, often custom to the patient.
- The defendant base is fragmented: hundreds of compounding pharmacies, telehealth platforms, prescribers, and resellers — most without the financial resources of a brand pharmaceutical company.
- Causation is harder to prove. Compounded products are not subject to the same FDA labeling, batch testing, and adverse-event reporting requirements as brand-name drugs.
- As of the date of this page, no federal MDL has been established for compounded-semaglutide injuries.
What are your realistic options?
- Request your dispensing records from the compounding pharmacy or telehealth provider. Sometimes patients are surprised to learn they actually received brand-name product through that channel. If you received brand-name Ozempic, Wegovy, Rybelsus, Mounjaro, Trulicity, Zepbound, Saxenda, or Victoza, you may have a viable case — visit our GLP-1 hub.
- If the records confirm the product was compounded, your situation is most likely an individual matter under state product-liability or pharmacy-malpractice law rather than a mass-tort claim. Cases like that are typically pursued individually rather than through an MDL.
- Report your adverse event to FDA MedWatch at fda.gov/safety/medwatch. This helps build the public record that may, eventually, support a future mass-tort consolidation.
- Preserve everything: the bottle or vial, the label, telehealth invoices, prescription paperwork, your medical records, and a written timeline of what you took, when, and what symptoms followed.
We will tell you honestly.
If you call our office, the first thing we will ask is: “Was the medication brand-name Ozempic, Wegovy, Rybelsus, Mounjaro, Trulicity, Zepbound, Saxenda, or Victoza — or was it compounded?” If it was compounded, we will tell you that immediately, and we will not waste your time. If you are not sure, bring your prescription bottle, pharmacy paperwork, or telehealth invoice and we will help you find out.
About this guidance
The information on this page reflects the current state of the GLP-1 mass-tort landscape and the case-acceptance criteria currently in effect for these claims. It is not legal advice for your specific case. If the litigation landscape changes — for example, if a federal MDL is later created for compounded semaglutide — we will update this page.
Contact our office if you have questions.